Spruce Biosciences, Inc. Payments of Debt Issuance Costs
Spruce Biosciences, Inc. (SPRB) reported Payments of Debt Issuance Costs of $10.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2023-03-16
- Spruce Biosciences, Inc. payments of debt issuance costs for the quarter ending 2022-12-31 was $0.00.
- Spruce Biosciences, Inc. payments of debt issuance costs for the quarter ending 2022-09-30 was $0.00.
- Spruce Biosciences, Inc. payments of debt issuance costs for the quarter ending 2022-06-30 was $0.00.
- Spruce Biosciences, Inc. payments of debt issuance costs for the quarter ending 2022-03-31 was $10.00K, a 0.00% change year-over-year.
- Spruce Biosciences, Inc. payments of debt issuance costs for fiscal 2022 was $10.00K, a 0.00% change from fiscal 2021.
- Spruce Biosciences, Inc. payments of debt issuance costs for fiscal 2021 was $10.00K.
- Spruce Biosciences, Inc. payments of debt issuance costs for fiscal 2019 was $8.00K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-16 | $0.00 derived: sum of 3 quarters · filed 2023-03-16 | $10.00K 10-K · filed 2023-03-16 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $10.00K 10-Q · filed 2022-11-10 | $10.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $10.00K 10-Q · filed 2022-08-10 | $10.00K derived: sum of 3 quarters · filed 2022-08-10 | $10.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2022-03-31 | $10.00K 10-Q · filed 2022-05-11 | $10.00K derived: sum of 2 quarters · filed 2022-05-11 | $10.00K derived: sum of 3 quarters · filed 2022-05-11 | $10.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $0.00 derived: sum of 2 quarters · filed 2022-03-14 | $0.00 derived: sum of 3 quarters · filed 2022-03-14 | $10.00K 10-K · filed 2022-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $10.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $10.00K 10-Q · filed 2021-08-10 | ||
| 2021-03-31 | $10.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $8.00K 10-K · filed 2021-03-22 | ||
| 2019-09-30 | $8.00K 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |